Month: September 2024

The Novian software and IT infrastructure services group had aggregated revenue of EUR 16.4 million in the first half of 2024. That is 11.1% less than in the same period last year. The group’s EBITDA was EUR 1.1 million; in the year-earlier period it was EUR 0.2 million. The operating profit for this year’s first six months was EUR 0.6 million, compared to an operating loss of EUR 0.3 million the first half of 2023. In the reporting period, the Novian group’s companies earned EUR 12.6 million of their revenue, or 77%, in Lithuania, and had projects in a total of 36 countries. “The results for the first half of the year reflect our work to lay strong foundations for further business growth. We believe that the competencies of our companies and specialists will allow us to continue to successfully meet clients’ needs, with effective...

The TGS presentation for the Pareto Securities Energy Conference can be downloaded at www.newsweb.no or www.tgs.com. CEO Kristian Johansen will present today at 12:10 CEST at the conference.  For more information, visit TGS.com or contact: Bård Stenberg  VP IR & Communication Mobile: +47 992 45 235 investor@tgs.com AttachmentPareto Securities Energy Conference

Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% shareholding in PanTera and following the closing and the subsequent capital increases, IBA will ultimately retain a 31.3% participation. The transaction will lead to a revaluation of IBA’s participation in PanTera, with a total positive impact of approximately EUR 23 million, which will be recognized as a profit to IBA over the next three years. PanTera secures EUR 93 million in oversubscribed...

Coop Pank’s financial results in August 2024:In August, number of the bank’s clients increased by 1,800 and number of active clients decreased by 2 200. By the end of the month number of clients reached 199,500 and number of active clients reached 87,900. Over the year, customer base has grown by 14%. Volume of the bank’s customer deposits increased by 34 million euros, reaching 1.83 billion euros by the end of month. Deposits of corporate customers increased by 5 million euros and deposits of private customers increased by 3 million euros. The volume of deposits attracted from international platforms increased by 26 million euros. Over the year, volume of bank deposits has grown by 7%. The bank’s loan portfolio increased by 8 million euros and reached 1.64 billion euros by the end of month. Home loans increased by...

  Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyStudy met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European UnionParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times...

  Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSUConfirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines Data will support regulatory resubmission in the US by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with...

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines Data will support regulatory resubmission in the U.S. by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) confirmatory Phase 3 trial (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the trial, five times more Dupixent patients achieved sustained disease remission...

FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected...

SIMPPLE Australia Pty Ltd launches SIMPPLE Robotics for the Australia and New Zealand marketsSIMPPLE Australia team at ISSA Expo 2024 SydneySYDNEY, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) — SIMPPLE Australia Pty Ltd, a subsidiary of SIMPPLE Ltd. (NASDAQ: SPPL, “SIMPPLE”, “the Company”) and a leading technology provider in the integrated facility management sector, is launching its latest line-up of robotic solutions (SIMPPLE Robotics) in the Australia and New Zealand (ANZ) market. SIMPPLE Australia Pty Ltd is excited to unveil its latest range of advanced cleaning and multi-functional robots at the ISSA Cleaning & Hygiene Expo 2024 in Sydney, Australia. This new robotic lineup features top-of-the-line proven industry solutions, including the recently developed multi-functional robot, Gemini, all of which are integrated...